Owner only: item control page
Al Malki, Monzr M. ; London, Kaitlyn ; Baez, Janna ; Akahoshi, Yu 
; Hogan, William J. ; Etra, Aaron ; Choe, Hannah ; Hexner, Elizabeth ; Langston, Amelia ; Abhyankar, Sunil ; Ponce, Doris M. ; DeFilipp, Zachariah ; Kitko, Carrie L. ; Adekola, Kehinde ; Reshef, Ran ; Ayuk, Francis ; Capellini, Alexandra ; Chanswangphuwana, Chantiya ; Eder, Matthias ; Eng, Gilbert ; Gandhi, Isha ; Grupp, Stephan ; Gleich, Sigrun ; Holler, Ernst ; Javorniczky, Nora Rebeka ; Kasikis, Stelios ; Kowalyk, Steven ; Morales, George ; Özbek, Umut ; Rösler, Wolf ; Spyrou, Nikolaos ; Yanik, Gregory ; Young, Rachel ; Chen, Yi-Bin ; Nakamura, Ryotaro ; Ferrara, James L. M. ; Levine, John E.
; Hogan, William J. ; Etra, Aaron ; Choe, Hannah ; Hexner, Elizabeth ; Langston, Amelia ; Abhyankar, Sunil ; Ponce, Doris M. ; DeFilipp, Zachariah ; Kitko, Carrie L. ; Adekola, Kehinde ; Reshef, Ran ; Ayuk, Francis ; Capellini, Alexandra ; Chanswangphuwana, Chantiya ; Eder, Matthias ; Eng, Gilbert ; Gandhi, Isha ; Grupp, Stephan ; Gleich, Sigrun ; Holler, Ernst ; Javorniczky, Nora Rebeka ; Kasikis, Stelios ; Kowalyk, Steven ; Morales, George ; Özbek, Umut ; Rösler, Wolf ; Spyrou, Nikolaos ; Yanik, Gregory ; Young, Rachel ; Chen, Yi-Bin ; Nakamura, Ryotaro ; Ferrara, James L. M. ; Levine, John E. Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease
Al Malki, Monzr M., London, Kaitlyn, Baez, Janna, Akahoshi, Yu, Hogan, William J. , Etra, Aaron, Choe, Hannah, Hexner, Elizabeth , Langston, Amelia , Abhyankar, Sunil, Ponce, Doris M., DeFilipp, Zachariah, Kitko, Carrie L., Adekola, Kehinde, Reshef, Ran, Ayuk, Francis, Capellini, Alexandra, Chanswangphuwana, Chantiya, Eder, Matthias, Eng, Gilbert, Gandhi, Isha, Grupp, Stephan, Gleich, Sigrun, Holler, Ernst, Javorniczky, Nora Rebeka, Kasikis, Stelios, Kowalyk, Steven, Morales, George, Özbek, Umut, Rösler, Wolf, Spyrou, Nikolaos, Yanik, Gregory, Young, Rachel, Chen, Yi-Bin, Nakamura, Ryotaro, Ferrara, James L. M. and Levine, John E.
(2023)
Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease.
Blood Advances 7 (17), pp. 5189-5198.
Date of publication of this fulltext: 18 Mar 2025 10:11
Article
Alternative links to fulltext
Involved Institutions
Details
| Item type | Article | ||||
| Journal or Publication Title | Blood Advances | ||||
| Publisher: | ELSEVIER | ||||
|---|---|---|---|---|---|
| Place of Publication: | AMSTERDAM | ||||
| Volume: | 7 | ||||
| Number of Issue or Book Chapter: | 17 | ||||
| Page Range: | pp. 5189-5198 | ||||
| Date | 2023 | ||||
| Institutions | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) | ||||
| Identification Number |
| ||||
| Keywords | CELL TRANSPLANTATION; PREVENTION; VEDOLIZUMAB; BIOMARKER; CYCLOPHOSPHAMIDE; BLOCKADE; THERAPY; BLOOD; TRIAL; SCORE; | ||||
| Dewey Decimal Classification | 600 Technology > 610 Medical sciences Medicine | ||||
| Status | Published | ||||
| Refereed | Yes, this version has been refereed | ||||
| Created at the University of Regensburg | Yes | ||||
| Item ID | 76291 |
Export bibliographical data
Owner only: item control page
Altmetric
Altmetric